A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C Patients

NCT00801255 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

88

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: RO5024048
DRUG: danoprevir
DRUG: danoprevir
DRUG: danoprevir
DRUG: danoprevir
DRUG: danoprevir

Sponsor

Hoffmann-La Roche